MTOR and breast cancer: Analysis of HER2 downstream signals in BC cells by WB showed that high activation of mTOR pathway components (pmTOR, pp70S6K) could distinguish ER-positive BC from ER-negative BC cells independently of their HER2 addiction status (Figure 4d).